Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

The Cooper Companies, Inc. (COO) SEC Filings & Earnings Calls

EquiReason read 13 The Cooper Companies, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-09-09 — The Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved .

Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason

COOThe Cooper Companies, Inc.Follow COO — free
Medical Instruments & Supplies · Healthcare
—
Price chart with a free account
Market cap
11.6B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
2 Dec, in 39 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

9 Sep 202610-QThe Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved operating performance, partially offset by a $272.0M litigatearningsopen

Figures in the filing · each found in the filing text

Net sales · Q3-2026$1.07B+1% y/y
Net income · Q3-2026$433M+340% y/y
Diluted earnings per share · Q3-2026$2.24+357% y/y
Gross margin · Q3-202666.8%
Operating cash flow · 9M-2026$785M+43% y/y
CooperVision revenue · CooperVision · Q3-2026$717M-0% y/y
CooperSurgical revenue · CooperSurgical · Q3-2026$349M+2% y/y
Free cash flow · 9M-2026$528M+93% y/y

Risks flagged

Litigation liability from product recall

“For the nine months ended July 31, 2026, the net impact to the consolidated statements of operations to resolve outstanding claims was $272.0 million, consisting of $325.8 million accrued litigation liability, partially offset by $53.8 million of insurance recoveries” · word for word

HMRC payroll tax dispute

“Depending on the results of the appeal, the Company could prevail on some or all of the issues in dispute, which could result in an obligation to pay a portion or all of the assessed amounts, with an estimated loss ranging from £0 to £71.7 million, plus accrued interest.” · word for word
Read the original on SEC EDGAR ↗
9 Sep 20268-K · 2.02, 8.01CooperCompanies completed strategic review, increased share repurchase authorization from $2B to $3B, with ~$1.5B remaining. Q3 FY2026 revenue $1.066B (+1% y/y), non-GAAP EPS $1.15 (+4%), free cash flow $273M (+66%). Guidance updated: FY202open

Figures in the filing · each found in the filing text

Revenue · total · Q3-2026$1.07B+1% y/y
GAAP diluted EPS · total · Q3-2026$2.24+357% y/y
Non-GAAP diluted EPS · total · Q3-2026$1.15+4% y/y
Free cash flow · total · Q3-2026$273M+66% y/y
Operating cash flow · total · Q3-2026$342M
Capital expenditures · total · Q3-2026$69M
Gross margin · total · Q3-202667.0%
Non-GAAP gross margin · total · Q3-202667.0%
Operating margin · total · Q3-202621.0%
Non-GAAP operating margin · total · Q3-202626.0%

Guidance

FY2026 total revenue $4.229-4.252B (organic 2-3%); CVI $2.828-2.842B (organic 1-2%); CSI $1.401-1.410B (organic 4-5%); FY2026 non-GAAP diluted EPS $4.51-4.55; Q4 FY2026 total revenue $1.057-1.080B (organic 0-2%); CVI $692-706M (organic -2% to 0%); CSI $364-374M (organic 4-6%); Q4 non-GAAP diluted EPS $1.05-1.09

Guidance updated: FY2026 revenue and EPS ranges provided; Q4 CVI organic growth expected -2% to 0% reflecting US channel inventory headwinds; CSI organic growth 4-6% remains solid; overall demand mixed but management tone positive on strategic review completion and cash generation

Risks flagged

CooperVision US channel inventory reduction weighing on results and expected to continue into Q4

“At CooperVision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4” · word for word

Unfavorable foreign exchange impacting gross margin and operating margin

“non-GAAP gross margin down 60bps driven by higher manufacturing costs and unfavorable foreign exchange; operating margin partially offset by unfavorable foreign exchange”

Higher manufacturing costs pressuring gross margin

“non-GAAP gross margin down 60bps driven by higher manufacturing costs and unfavorable foreign exchange”
Read the original on SEC EDGAR ↗
5 Jun 202610-QNet sales $1.08B (+8% y/y); Net income (loss) $-78M; Diluted earnings (loss) per share $-0.40open

Figures in the filing · each found in the filing text

Net sales · Total · Q2-2026$1.08B+8% y/y
Net income (loss) · Q2-2026$-78M
Diluted earnings (loss) per share · Q2-2026$-0.40
CooperVision net sales · CooperVision · Q2-2026$724M+8% y/y
CooperSurgical net sales · CooperSurgical · Q2-2026$358M+8% y/y
CooperVision operating income · CooperVision · Q2-2026$216M+16% y/y
CooperSurgical operating income (loss) · CooperSurgical · Q2-2026$-225M
Operating cash flow · H1-2026$444M+55% y/y
Capital expenditures · H1-2026$189M+13% y/y
Share repurchases · H1-2026$108M+166% y/y

Risks flagged

Embryo culture media litigation

“The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million, consisting of $324.1 million accrued litigation liability, partially offset by $52.5 million of insurance recoveries.” · word for word

HMRC tax dispute

“estimated loss ranging from £0 to £71.7 million, plus accrued interest” · word for word

Tariff and trade barrier risk

“These risks include ... escalating global trade barriers and disruptions, such as the impact of tariffs.”

Asia Pacific revenue softness

“Asia Pacific 130.6 138.6 (6)%” · word for word
Read the original on SEC EDGAR ↗
4 Jun 20268-K · 2.02, 8.01Revenue $1.08B (+8% y/y); GAAP diluted EPS $-0.40; Non-GAAP diluted EPS $1.21 (+26% y/y)earningsopen

Figures in the filing · each found in the filing text

Revenue · total · Q2-2026$1.08B+8% y/y
GAAP diluted EPS · total · Q2-2026$-0.40
Non-GAAP diluted EPS · total · Q2-2026$1.21+26% y/y
Gross margin · total · Q2-202668.0%
Operating margin (GAAP) · total · Q2-2026-3.0%
Non-GAAP operating margin · total · Q2-202627.0%
Interest expense · total · Q2-2026$21M-14% y/y
Cash provided by operations · total · Q2-2026$183M
Capital expenditures · total · Q2-2026$86M
Free cash flow · total · Q2-2026$96M

Risks flagged

Product recall litigation risk largely resolved with >95% claims settled, but $271.6M charge impacts GAAP earnings and cash flow.

“The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million... The Company currently expects the majority of the payments to be made during fiscal 2026.” · word for word
Read the original on SEC EDGAR ↗
4 May 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
6 Mar 202610-QCooper Companies reported Q1 FY2026 revenue of $1.024B (+6.2% YoY) and EPS of $0.66 (+26.9% YoY), with strong operating cash flow and segment margin expansion.earningsopen

Figures in the filing · each found in the filing text

Net sales · Q1-2026$1.02B+6% y/y
Net income · Q1-2026$131M+25% y/y
Diluted earnings per share · Q1-2026$0.66+27% y/y
Gross margin · Q1-202668.0%
Operating cash flow · Q1-2026$261M+37% y/y
Free cash flow · Q1-2026$158M+68% y/y
CooperVision net sales · CooperVision · Q1-2026$695M+8% y/y
CooperSurgical net sales · CooperSurgical · Q1-2026$329M+3% y/y

Risks flagged

UK Tax Dispute

“Estimated loss ranging from £0 to £71.7 million, plus accrued interest, related to HMRC payroll tax dispute.” · word for word

Foreign Exchange Exposure

“A uniform hypothetical 10% increase or decrease in foreign currency exchange rates would result in a corresponding increase or decrease of approximately $34.9 million in operating income.” · word for word
Read the original on SEC EDGAR ↗
5 Mar 20268-K · 2.02Revenue $1.02B (+6% y/y); GAAP Diluted EPS $0.66 (+27% y/y); Non-GAAP Diluted EPS $1.10 (+20% y/y); Guidance: Non-GAAP EPS $4.58-$4.66; FCF $600-$625Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$1.02B+6% y/y
GAAP Diluted EPS · Q1-2026$0.66+27% y/y
Non-GAAP Diluted EPS · Q1-2026$1.10+20% y/y
Free Cash Flow · Q1-2026$159M
CooperVision Revenue · CooperVision · Q1-2026$695M+8% y/y
CooperSurgical Revenue · CooperSurgical · Q1-2026$329M+3% y/y
Gross Margin · Q1-202668.0%
Non-GAAP Operating Margin · Q1-202627.0%
Share Repurchases · Q1-2026$93M

Guidance

Non-GAAP EPS $4.58-$4.66; FCF $600-$625M

Raised FY2026 non-GAAP EPS and free cash flow guidance based on strong Q1 results and positive outlook.

Risks flagged

Tariff impact on gross margin; excluding tariffs, gross margin would have been flat YoY.

“Excluding the impact of tariffs, gross margin would have been flat year over year.” · word for word
Read the original on SEC EDGAR ↗
24 Feb 2026DEF 14AProxy statement filed for annual shareholder meeting, detailing executive compensation, governance, and fiscal 2025 performance.open

Figures in the filing · each found in the filing text

Revenue · FY2025$4.09B+5% y/y
Non-GAAP Diluted EPS · FY2025$4.13+12% y/y
Free Cash Flow · FY2025$434M
GAAP Gross Margin · FY202566.0%
Non-GAAP Gross Margin · FY202568.0%
GAAP Operating Margin · FY202517.0%
Non-GAAP Operating Margin · FY202526.0%
CooperVision Revenue · CooperVision · FY2025$2.74B+5% y/y
CooperSurgical Revenue · CooperSurgical · FY2025$1.35B+5% y/y
Share Repurchases · FY2025$290M

Guidance

Long-term free cash flow target raised to $2.2B+ through fiscal 2028; buyback authorization expanded to $2B

Management raised long-term free cash flow target and expanded buyback, signaling confidence in future cash generation.

Risks flagged

Restructuring execution risk

“During the fourth quarter of fiscal 2025, the Company completed significant reorganization and integration activity.” · word for word

High capex burden

“capital expenditures of $362.4 million” · word for word
Read the original on SEC EDGAR ↗
4 Feb 20268-K · 1.01Cooper Companies amended its term loan and revolving credit agreements, extending $950M of term loans to 2031 and increasing incremental loan cap to $1.365B.SEC ↗
23 Dec 20258-K · 1.01, 5.02, 7.01Entered a material definitive agreement (acquisition, partnership, or major contract); reported the departure of a director or principal officer (CEO/CFO change)open

Risks flagged

Activist involvement may lead to strategic shifts or pressure for operational changes, but cooperation agreement reduces near-term disruption risk.

“Browning West agreed to standstill restrictions and voting commitments through 2027 annual meeting period.”
Read the original on SEC EDGAR ↗
12 Dec 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
5 Dec 202510-KRevenue $4.09B (+5% y/y); Operating Cash Flow $796M (+12% y/y); Gross Margin 66open

Figures in the filing · each found in the filing text

Revenue · Consolidated · FY2025$4.09B+5% y/y
Operating Cash Flow · Consolidated · FY2025$796M+12% y/y
Gross Margin · Consolidated · FY202566.0%
CooperVision Revenue · CooperVision · FY2025$2.74B+5% y/y
CooperSurgical Revenue · CooperSurgical · FY2025$1.35B+5% y/y
Americas Revenue · CooperVision Americas · FY2025$1.12B+5% y/y
EMEA Revenue · CooperVision EMEA · FY2025$1.06B+8% y/y
Asia Pacific Revenue · CooperVision Asia Pacific · FY2025$555M0% y/y

Risks flagged

Regulatory risk for genetic testing

“Increased regulatory scrutiny of genetic testing may adversely affect our business through increased costs and risks associated with gaining marketing approvals or certifications and potential impact on demand for our genetic testing services.” · word for word

Currency exposure

“Our most significant currency exposures are the British pound, Euro and Japanese yen.” · word for word

Debt covenant risk

“Our credit facilities contain financial and other restrictive covenants that could limit our ability to engage in activities that may be in our long-term best interests.” · word for word
Read the original on SEC EDGAR ↗
4 Dec 20258-K · 2.02, 5.02, 7.01Revenue $1.07B (+5% y/y); Non-GAAP diluted EPS $1.15 (+11% y/y); GAAP diluted EPS $0.43 (-27% y/y); Guidance: Free cash flow >$2.2B cumulative 2026-2028earningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$1.07B+5% y/y
Non-GAAP diluted EPS · Q4-2025$1.15+11% y/y
GAAP diluted EPS · Q4-2025$0.43-27% y/y
Free cash flow · Q4-2025$150M
CooperVision revenue · CooperVision · Q4-2025$710M+5% y/y
CooperSurgical revenue · CooperSurgical · Q4-2025$356M+4% y/y
Non-GAAP gross margin · Q4-202566.0%
Non-GAAP operating margin · Q4-202527.0%
MiSight revenue growth · CooperVision · Q4-202537.0%

Guidance

Free cash flow >$2.2B cumulative 2026-2028

Raised FCF guidance; earnings beat; positive outlook for 2026.

Risks flagged

GAAP EPS down 27% due to reorganization costs; gross margin pressure from tariffs and mix.

“GAAP diluted EPS of $0.43, down 27%... Non-GAAP gross margin was down 70 basis points... primarily from tariffs and mix.”
Read the original on SEC EDGAR ↗

The Cooper Companies, Inc. — questions

What did The Cooper Companies, Inc. file recently?
13 SEC filings in the last 12 months. Latest: 10-Q on 2026-09-09 — The Cooper Companies reported Q3 2026 results with net income of $432.8M (diluted EPS $2.24) vs $98.3M ($0.49) in prior year, driven by a $307.2M discrete tax benefit and improved operating performance, partially offset by a $272.0M litigat

Every figure on this page comes from The Cooper Companies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.